Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant grass pollen immunotherapy in allergic rhinoconjunctivitis
NCT00309036Phase 3Completed
- Sponsor
- Allergopharma
- Start
- Jan 2004
- Primary completion
- Sep 2006
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of recombinant timothy grass pollen allergen cocktail in allergic rhinoconjunctivitis (ARC) (2 arms), sponsored by Allergopharma. Primary endpoint: Symptom Medication Score. Started Jan 2004; status: completed.
02
Drugs
recombinant timothy grass pollen allergen cocktail
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT00309036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00309036.